Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy

被引：65

作者：

Riihijarvi, Sari ^{[1
,2
]}

Taskinen, Minna ^{[1
,2
]}

Jerkeman, Mats ^{[3
]}

Leppa, Sirpa ^{[1
,2
]}

机构：

[1] Univ Helsinki, Cent Hosp, Dept Oncol, FIN-00029 Helsinki, Finland

[2] Univ Helsinki, Biomedicum Helsinki, Genome Scale Biol Res Program, FIN-00029 Helsinki, Finland

[3] Lund Univ, Dept Oncol, Lund, Sweden

来源：

EUROPEAN JOURNAL OF HAEMATOLOGY | 2011年 / 86卷 / 02期

关键词：

B-cell non-Hodgkin lymphoma; prognostic factors; gender; immunochemotherapy; CHEMOTHERAPY PLUS RITUXIMAB; RANDOMIZED CONTROLLED-TRIAL; FOLLICULAR LYMPHOMA; ELDERLY-PATIENTS; CHOP;

D O I：

10.1111/j.1600-0609.2010.01541.x

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Male gender is an adverse prognostic factor in Hodgkin's lymphoma, but no such association has yet been established in non-Hodgkin lymphomas. Here, we have evaluated whether gender has prognostic impact on the survival of patients with B-cell non-Hodgkin lymphoma in the postrituximab era of lymphoma therapies. The study populations consisted of 217 diffuse large B-cell lymphoma (DLBCL) and 110 follicular lymphoma (FL) patients treated with immunochemotherapy. Hundred and sixty chemotherapy-treated DLBCL patients served as a control group. According to Kaplan-Meier analyses, female patients had a significantly better progression-free survival than men both in DLBCL (4 yr PFS 75% vs. 60%; P = 0.013) and in FL (4 yr PFS 68% vs. 52%, P = 0.036) patients treated with immunochemotherapy. In chemotherapy-treated DLBCL patients, no difference in survival between the genders was found. The results support the idea that women seem to respond better to rituximab.

引用

页码：124 / 128

页数：5

共 12 条

[1]

Glutathione-S-transferase genotypes influence the risk of chemotherapy-related toxicities and prognosis in Korean patients with diffuse large B-cell lymphoma [J].

Cho, Hyun-Jung ;

Eom, Hyeon-Seok ;

Kim, Hyun-Ju ;

Kim, In-Suk ;

Lee, Gyeong Won ;

Kong, Sun-Young .

CANCER GENETICS AND CYTOGENETICS, 2010, 198 (01) :40-46

[2]

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].

Coiffier, B ;

Lepage, E ;

Brière, J ;

Herbrecht, R ;

Tilly, H ;

Bouabdallah, R ;

Morel, P ;

Van den Neste, E ;

Salles, G ;

Gaulard, P ;

Reyes, F ;

Gisselbrecht, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242

[3]

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma [J].

Habermann, Thomas M. ;

Weller, Edie A. ;

Morrison, Vicki A. ;

Gascoyne, Randy D. ;

Cassileth, Peter A. ;

Cohn, Jeffrey B. ;

Dakhil, Shaker R. ;

Woda, Bruce ;

Fisher, Richard I. ;

Peterson, Bruce A. ;

Horning, Sandra J. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (19) :3121-3127

[4]

Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma:: An East German Study Group hematology and oncology study [J].

Herold, Michael ;

Haas, Antje ;

Srock, Stefanie ;

Neser, Sabine ;

Al-Ali, Kathrin Haifa ;

Neubauer, Andreas ;

Doelken, Gottfried ;

Naumann, Ralph ;

Knauf, Wolfgang ;

Freund, Mathias ;

Rohrberg, Robert ;

Hoeffken, Klaus ;

Franke, Astrid ;

Ittel, Thomas ;

Kettner, Erika ;

Haak, Ursula ;

Mey, Ulrich ;

Klinkenstein, Christian ;

Assmann, Michael ;

von Gruenhagen, Ullrich .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (15) :1986-1992

[5]

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group [J].

Hiddemann, W ;

Kneba, M ;

Dreyling, M ;

Schmitz, N ;

Lengfelder, E ;

Schmits, R ;

Reiser, M ;

Metzner, B ;

Harder, H ;

Hegewisch-Becker, S ;

Fischer, T ;

Kropff, M ;

Reis, HE ;

Freund, M ;

Wörmann, B ;

Fuchs, R ;

Planker, M ;

Schimke, J ;

Eimermacher, H ;

Trümper, L ;

Aldaoud, A ;

Parwaresch, R ;

Unterhalt, M .

BLOOD, 2005, 106 (12) :3725-3732

[6]

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma [J].

Marcus, R ;

Imrie, K ;

Belch, A ;

Cunningham, D ;

Flores, E ;

Catalano, J ;

Solal-Celigny, P ;

Offner, F ;

Walewski, J ;

Raposo, J ;

Jack, A ;

Smith, P .

BLOOD, 2005, 105 (04) :1417-1423

[7]

Prognostic factors in patients with diffuse large B cell lymphoma: Before and after the introduction of rituximab [J].

Ngo, Lynette ;

Hee, Siew-Wan ;

Lim, Lay-Cheng ;

Tao, Miriam ;

Quek, Richard ;

Yap, Swee-Peng ;

Loong, Er-Li ;

Sng, Ivy ;

Hwan-Cheong, Tan Leonard ;

Ang, Mei-Kim ;

Ngeow, Joanne ;

Tham, Chee-Kian ;

Tan, Min-Han ;

Lim, Soon-Thye .

LEUKEMIA & LYMPHOMA, 2008, 49 (03) :462-469

[8]

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas:: a randomised controlled trial (RICOVER-60) [J].

Pfreundschuh, Michael ;

Schubert, Joerg ;

Ziepert, Marita ;

Schmits, Rudolf ;

Mohren, Martin ;

Lengfelder, Eva ;

Reiser, Marcel ;

Nickenig, Christina ;

Clemens, Michael ;

Peter, Norma ;

Bokemeyer, Carsten ;

Eimermacher, Hartmut ;

Ho, Anthony ;

Hoffmann, Martin ;

Mertelsmann, Roland ;

Truemper, Lorenz ;

Balleisen, Leopold ;

Liersch, Ruediger ;

Metzner, Bernd ;

Hartmann, Frank ;

Glass, Bertram ;

Poeschel, Viola ;

Schmitz, Norbert ;

Ruebe, Christian ;

Feller, Alfred C. ;

Loeffler, Markus .

LANCET ONCOLOGY, 2008, 9 (02) :105-116

[9]

Male Sex Is Associated with Lower Rituximab Trough Serum Levels and Evolves as a Significant Prognostic Factor in Elderly Patients with DLBCL Treated with R-CHOP: Results From 4 Prospective Trials of the German High-Grade Non-Hodgkin-Lymphoma Study Group (DSHNHL). [J].

Pfreundschuh, Michael ;

Murawski, Niels ;

Zeynalova, Samira ;

Poeschel, Viola ;

Reiser, Marcel ;

Ho, Anthony D. ;

Nickenig, Christina ;

Wessendorf, Swen ;

Metzner, Bernd ;

Grass, Sandra ;

Schubert, Joerg ;

Loeffler, Markus ;

Schmitz, Norbert .

BLOOD, 2009, 114 (22) :1431-1431

[10]

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma:: a randomised controlled trial by the MabThera International Trial (MInT) Group [J].

Pfreundschuh, Michael ;

Trumper, Lorenz ;

Osterborg, Anders ;

Pettengell, Ruth ;

Trneny, Marek ;

Imrie, Kevin ;

Ma, David ;

Gill, Devinder ;

Walewski, Jan ;

Zinzani, Pier-Luigi ;

Stahel, Rolf ;

Kvaloy, Stein ;

Shpilberg, Ofer ;

Jaeger, Ulrich ;

Hansen, Mads ;

Lehtinen, Tuula ;

Lopez-Guillermo, Armando ;

Corrado, Claudia ;

Scheliga, Adriana ;

Milpied, Noel ;

Mendila, Myriam ;

Rashford, Michelle ;

Kuhnt, Evelyn ;

Loeffler, Markus .

LANCET ONCOLOGY, 2006, 7 (05) :379-391

← 1 2 →